Skip to main content
. 2014 Nov 4;4:6899. doi: 10.1038/srep06899

Figure 4. ABCB4 expression in cancer cells, reexpression under DNMT inhibitor treatment.

Figure 4

(A). Expression analysis of ABCB4 is shown after 5-aza-2’-deoxycytidine (Aza) and zebularine (Zebu) treatments in lung cancer cell lines A427, A549, H322, HCC-15 and HTB-171, breast cancer ZR-75-1, head and neck cancer RPMI-2650 and melanoma SK-Mel-13. ABCB4 (185 bp) and ACTB (226 bp) expression was analyzed by RT-PCR after four days of Aza or Zebu treatment on 2% gel with 100 bp marker (M). (B). Lung cancer H1299 cells treated with either 5 μM Aza or 200 μM Zebu for 72 h. Cells were blocked with 5% BSA for 1 h, followed by incubation with anti-ABCB4 antibody overnight at 4°C. Finally, cells were incubated with Alexa Fluor 488-conjugated secondary antibody and nuclei were stained with DAPI. Representative images are shown.